NCT04729621View on ClinicalTrials.gov

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

PHASE3CompletedINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

March 22, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

June 19, 2023

Conditions
Osteoporosis, Postmenopausal
Interventions
COMBINATION_PRODUCT

TVB-009

TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)

COMBINATION_PRODUCT

Prolia®

Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)

Trial Locations (78)

16635

Teva Site 108, Duncansville

32055

Teva Site 116, Lake City

32132

Teva Site 114, Edgewater

32174

Teva Site 102, Ormond Beach

32801

Teva Site 120, Orlando

33014

Teva Site 109, Miami Lakes

33134

Teva Site 115, Coral Gables

33166

Teva Site 117, Miami Springs

33321

Teva Site 104, Tamarac

34239

Teva Site 111, Sarasota

34677

Teva Site 110, Oldsmar

34952

Teva Site 101, Port Saint Lucie

85004

Teva Site 103, Phoenix

85704

Teva Site 119, Tucson

87106

Teva Site 105, Albuquerque

89014

Teva Site 112, Henderson

89030

Teva Site 113, North Las Vegas

92111

Teva Site 118, San Diego

98105

Teva Site 106, Seattle

06320

Teva Site 107, New London

Unknown

Teva Site 203, Blagoevgrad

Teva Site 207, Dimitrovgrad

Teva Site 252, Haskovo

Teva Site 202, Lom

Teva Site 205, Plovdiv

Teva Site 250, Silistra

Teva Site 201, Sofia

Teva Site 204, Sofia

Teva Site 251, Sofia

Teva Site 206, Stara Zagora

Teva Site 211, Brno

Teva Site 213, Ostrava

Teva Site 212, Pardubice

Teva Site 209, Prague

Teva Site 210, Prague

Teva Site 208, Uherské Hradiště

Teva Site 214, Tbilisi

Teva Site 215, Tbilisi

Teva Site 216, Tbilisi

Teva Site 217, Tbilisi

Teva Site 218, Tbilisi

Teva Site 219, Tbilisi

Teva Site 223, Dresden

Teva Site 220, Hamburg

Teva Site 221, Nümbrecht

Teva Site 222, Würzburg

Teva Site 226, Balatonfüred

Teva Site 225, Budapest

Teva Site 227, Budapest

Teva Site 253, Budapest

Teva Site 224, Nyíregyháza

Teva Site 228, Bialystok

Teva Site 233, Krakow

Teva Site 231, Lodz

Teva Site 230, Warsaw

Teva Site 232, Warsaw

Teva Site 229, Wroclaw

Teva Site 235, Moscow

Teva Site 236, Saint Petersburg

Teva Site 254, Saint Petersburg

Teva Site 255, Saint Petersburg

Teva Site 256, Saint Petersburg

Teva Site 257, Saint Petersburg

Teva Site 234, Yaroslavl

Teva Site 258, Yaroslavl

Teva Site 238, Bratislava

Teva Site 242, Bratislava

Teva Site 237, Hlohovec

Teva Site 241, Lučenec

Teva Site 240, Ľubochňa

Teva Site 239, Prešov

Teva Site 244, Kyiv

Teva Site 245, Kyiv

Teva Site 247, Kyiv

Teva Site 248, Kyiv

Teva Site 249, Kyiv

Teva Site 243, Vinnytsia

Teva Site 246, Zaporizhia

All Listed Sponsors
collaborator

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

lead

Teva Pharmaceuticals USA

INDUSTRY

NCT04729621 - A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis | Biotech Hunter | Biotech Hunter